[
    [
        {
            "time": "2021-08-30",
            "original_text": "康龙化成：高盛证券、海通证券等12家机构于8月30日调研我司",
            "features": {
                "keywords": [
                    "康龙化成",
                    "调研",
                    "高盛证券",
                    "海通证券",
                    "机构"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "康龙化成：高盛证券、海通证券等12家机构于8月30日调研我司",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-08-30",
            "original_text": "国盛证券维持康龙化成买入评级：主营增长强劲，服务边界持续拓宽值得期待",
            "features": {
                "keywords": [
                    "康龙化成",
                    "国盛证券",
                    "买入评级",
                    "主营增长",
                    "服务边界"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国盛证券维持康龙化成买入评级：主营增长强劲，服务边界持续拓宽值得期待",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-08-30",
            "original_text": "华金证券维持康龙化成增持评级：实验室龙头逐渐向全产业链延伸，大小分子和CGT有序扩产",
            "features": {
                "keywords": [
                    "康龙化成",
                    "华金证券",
                    "实验室龙头",
                    "全产业链",
                    "大小分子",
                    "CGT"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华金证券维持康龙化成增持评级：实验室龙头逐渐向全产业链延伸，大小分子和CGT有序扩产",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-08-30",
            "original_text": "中泰证券维持康龙化成买入评级：主业持续亮眼，四大板块助力多疗法、一体化平台长期成长",
            "features": {
                "keywords": [
                    "康龙化成",
                    "中泰证券",
                    "买入评级",
                    "主业",
                    "多疗法",
                    "一体化平台"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中泰证券维持康龙化成买入评级：主业持续亮眼，四大板块助力多疗法、一体化平台长期成长",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-08-30",
            "original_text": "康龙化成(300759)：主营业务保持强劲增长 期待产能有序推进",
            "features": {
                "keywords": [
                    "康龙化成",
                    "主营业务",
                    "强劲增长",
                    "产能推进"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康龙化成(300759)：主营业务保持强劲增长 期待产能有序推进",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-08-30",
            "original_text": "医疗健康行业动态：医药板块中报业绩稳健; 长期看好产业升级和国际化",
            "features": {
                "keywords": [
                    "医疗健康",
                    "医药板块",
                    "中报业绩",
                    "产业升级",
                    "国际化"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医疗健康行业动态：医药板块中报业绩稳健; 长期看好产业升级和国际化",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-08-30",
            "original_text": "康龙化成(300759)2021中报点评：收入端延续较快增长 大分子和CGT平台渐成型",
            "features": {
                "keywords": [
                    "康龙化成",
                    "2021中报",
                    "收入端",
                    "大分子",
                    "CGT平台"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康龙化成(300759)2021中报点评：收入端延续较快增长 大分子和CGT平台渐成型",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-08-30",
            "original_text": "康龙化成(300759)：成熟业务持续高增长 新型业务成长空间大",
            "features": {
                "keywords": [
                    "康龙化成",
                    "成熟业务",
                    "高增长",
                    "新型业务",
                    "成长空间"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康龙化成(300759)：成熟业务持续高增长 新型业务成长空间大",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]